Home » Market News » DirectorsTalk Highlights » Motif Bio plc 2 posters at ID Week in New Orleans
Motif Bio Plc

Motif Bio plc 2 posters at ID Week in New Orleans

Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, has told DirectorsTalk that it will be presenting two poster studies at IDWeek, October 26 to 30 in New Orleans, USA.


IDWeek is an annual gathering of 6,000 practitioners who are members of the Infectious Disease Society of America (IDSA), the Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA) and the Pediatric Infectious Diseases Society (PIDS) and represents the largest gathering of practicing professionals dedicated to the treatment, control and eradication of infectious diseases.


Motif Bio will be presenting two posters at the session titledAntimicrobial Pharmacokinetics and Pharmacodynamics’ on Saturday, October 29, 2016 between 12.30 and 2.00 pm.


The first poster is titled ‘The Use of PK/PD Systems Analyses to Determine the Optimal Fixed Dosing Regimen of Iclaprim (ICL) for a Phase III ABSSSI Clinical Trial’.


The second poster is titled ‘A 2012-2014 Global Antimicrobial Surveillance of Iclaprim Against Clinical Strains Causing Hospital-Associated Bacterial Pneumonia (HABP) and Skin and Skin Structure Infections (SSSI)’.

Disclaimer: Statements in this article should not be considered investment advice, which is best sought directly from a qualified professional.